GO:0097214 positive regulation of lysosomal membrane permeability: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097214 describes any process that increases the frequency, rate or extent of molecule passage or uptake across the lysosomal membrane [1, 6].
• Lysosomal membrane permeability is controlled by proteins such as DRAM, LAMP5, Rab7, Vps35, and KIF13B, which influence membrane stability, trafficking, and acidification [2, 4, 7, 8].
• Increased lysosomal membrane permeability can trigger cell death pathways and is implicated in HIV infection, intracerebral hemorrhage, senescence, and cancer [3, 4, 8].
• Experimental models for studying this process include CRISPR knockout, point mutation, knock-in, and overexpression cell lines targeting key regulators [1, 4, 7].
• Key methods include lysosomal membrane permeability assays, live-cell imaging, proteomics, and transcriptomics to quantify leakage and downstream effects [1, 3, 8].
• Dysregulation of lysosomal membrane permeability contributes to breast cancer resistance, neurodegeneration, and metabolic liver disease [1, 4, 5].
Description
The Gene Ontology term GO:0097214, positive regulation of lysosomal membrane permeability, refers to any process that increases the frequency, rate or extent of the passage or uptake of molecules by the lysosomal membrane [1, 6]. Lysosomes are acidic organelles responsible for degradation and recycling, and their membrane integrity is critical for cellular homeostasis. When permeability increases, lysosomal contents such as cathepsins can leak into the cytosol, potentially triggering cell death or signaling cascades. This process is distinct from general lysosomal function and is tightly regulated by proteins that modulate membrane stability, trafficking, and acidification [2, 4, 7]. Researchers study GO:0097214 because it sits at the intersection of lysosomal biology, cell death, and disease. For example, in HIV-infected CD4+ T cells, the protein DRAM triggers lysosomal membrane permeabilization and subsequent cell death. In breast cancer cells resistant to abemaciclib, lysosomal protein deregulation is associated with increased metastatic potential. Additionally, lysosome-mediated processing of chromatin during senescence highlights a role in aging and genome stability. Understanding the positive regulation of lysosomal membrane permeability can reveal therapeutic targets for cancer, neurodegeneration, and inflammatory conditions [4, 5]. This article provides a research-grade overview of GO:0097214, covering its definition, key genes, regulatory mechanisms, disease links, and experimental methods. All facts are based on published literature and the QuickGO definition, with citations to verified PMIDs.
positive regulation of lysosomal membrane permeability At A Glance
| GO ID | GO:0097214 |
|---|---|
| GO term | positive regulation of lysosomal membrane permeability |
| Ontology | biological_process |
| Synonym | positive regulation of lysosome membrane permeability |
| Definition | Any process that increases the frequency, rate or extent of the passage or uptake of molecules by the lysosomal membrane. |
| Major function | Regulation of lysosomal membrane integrity and permeability, influencing cell death and signaling. |
| Related processes | Lysosomal membrane permeabilization, lysosomal cell death, autophagy, senescence. |
| Key regulators | DRAM, LAMP5, Rab7, Vps35, KIF13B, and others. |
What Is GO:0097214?
GO:0097214 is defined as any process that increases the frequency, rate or extent of the passage or uptake of molecules by the lysosomal membrane. In other words, it encompasses molecular events that make the lysosomal membrane more permissive to the movement of substances into or out of the lysosome, often leading to the release of lysosomal contents into the cytosol or altered lysosomal function [1, 6].
Why Is positive regulation of lysosomal membrane permeability Important in Cell Biology?
Positive regulation of lysosomal membrane permeability is important because it controls the release of lysosomal contents, which can initiate cell death, modulate immune responses, and contribute to disease progression. Dysregulation of this process is linked to cancer, neurodegeneration, and metabolic disorders, making it a potential therapeutic target [1, 4, 5, 8].
• Controls lysosomal membrane permeabilization, a key step in lysosome-dependent cell death.
• Influences cancer cell resistance and metastatic potential, as seen in breast cancer cells resistant to abemaciclib.
• Plays a role in HIV pathogenesis by triggering CD4+ T cell death through DRAM.
• Contributes to brain injury after intracerebral hemorrhage via LAMP5.
• Linked to senescence through lysosome-mediated chromatin processing.
• Involved in metabolic liver disease and mitochondrial dysfunction.
• Regulates vascular permeability through KIF13B-mediated VEGFR2 recycling.
• Affects renal water transport via Rab7 and Vps35-mediated AQP2 trafficking.
• Provides targets for CRISPR-based functional studies and drug discovery [1, 4, 7].
• Serves as a biomarker for lysosomal dysfunction in multiple diseases [1, 4, 5].
What Happens During positive regulation of lysosomal membrane permeability?
Initiation by stress or signaling
In simple terms: A cell receives a signal or stress that tells the lysosome to become leaky.
Positive regulation of lysosomal membrane permeability can be initiated by various cellular stresses, including viral infection, oxidative stress, or chemotherapeutic agents. For example, in HIV-infected CD4+ T cells, the protein DRAM is induced and triggers lysosomal membrane permeabilization. Similarly, in breast cancer cells resistant to abemaciclib, lysosomal protein deregulation is associated with increased permeability.
Membrane modification and pore formation
In simple terms: The lysosomal membrane undergoes changes that create openings for molecules to pass through.
Upon initiation, proteins such as DRAM insert into or modify the lysosomal membrane, leading to pore formation or lipid rearrangement that increases permeability. Other proteins like LAMP5 may influence membrane stability, as observed in intracerebral hemorrhage models. The exact molecular events can involve proteases, lipids, and chaperones that collectively weaken the membrane barrier.
Release of lysosomal contents
In simple terms: Substances inside the lysosome leak out into the rest of the cell.
Increased permeability allows lysosomal contents, including cathepsins and other hydrolases, to leak into the cytosol. This release can activate cell death pathways, such as apoptosis or necrosis. In senescence, lysosome-mediated processing of chromatin involves the release of factors that modify chromatin, linking lysosomal permeability to gene expression changes.
Downstream cellular responses
In simple terms: The leaked contents cause the cell to react, often leading to cell death or adaptation.
The release of lysosomal contents triggers downstream signaling, including activation of caspases, mitochondrial dysfunction, and inflammatory responses. In HIV-infected T cells, this leads to cell death. In cancer, it may promote survival or resistance, as seen in abemaciclib-resistant breast cancer cells. In metabolic liver disease, restoring mitochondrial function can ameliorate disease, suggesting crosstalk between lysosomal permeability and metabolism.
Regulation by trafficking and acidification
In simple terms: The movement of proteins and the acidity of the lysosome can control how leaky it becomes.
Proteins involved in lysosomal trafficking, such as Rab7 and Vps35, mediate sorting and apical trafficking of AQP2 in collecting duct cells, indirectly affecting lysosomal function and membrane dynamics. KIF13B mediates VEGFR2 recycling to modulate vascular permeability, indicating that trafficking pathways can influence membrane permeability. Additionally, lysosomal acidification, as quantified in rat liver lysosomes, is a key parameter that can affect membrane stability.
Key Genes Involved in GO:0097214 positive regulation of lysosomal membrane permeability
The following genes and proteins have been experimentally linked to the positive regulation of lysosomal membrane permeability or related lysosomal membrane dynamics.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DRAM | Triggers lysosomal membrane permeabilization and cell death | Studied in HIV-infected CD4+ T cells; knockout reduces cell death |
| LAMP5 | Lysosomal-associated transmembrane protein 5; may stabilize membrane | Involved in brain injury after intracerebral hemorrhage; knockout worsens injury |
| Rab7 | Late endosomal/lysosomal trafficking; mediates AQP2 sorting | Regulates lysosomal positioning and membrane dynamics; knockout affects renal water transport |
| Vps35 | Retromer component; mediates AQP2 trafficking with Rab7 | Knockdown alters lysosomal trafficking and membrane permeability |
| KIF13B | Kinesin motor; mediates VEGFR2 recycling | Modulates vascular permeability; knockout affects endothelial function |
| Cathepsins | Lysosomal proteases; leak upon permeabilization | Biomarkers of lysosomal membrane permeabilization; inhibitors block cell death |
| mTOR | Regulates lysosomal biogenesis and autophagy | Inhibition can alter lysosomal membrane permeability |
| TFEB | Transcription factor for lysosomal genes | Overexpression increases lysosomal content and may affect permeability |
| LAMP1 | Lysosomal membrane protein; marker of lysosomes | Used to assess lysosomal membrane integrity |
| LAMP2 | Lysosomal membrane protein; protects membrane | Deficiency increases permeability and cardiomyopathy |
| Galectin-3 | Cytosolic lectin; binds leaked glycoproteins | Marker of lysosomal membrane permeabilization |
| Bax/Bak | Pro-apoptotic Bcl-2 proteins | Can induce lysosomal membrane permeabilization |
| p53 | Tumor suppressor; can transcriptionally activate DRAM | Regulates DRAM expression and lysosomal cell death |
| NF-κB | Inflammatory transcription factor | Modulates lysosomal permeability in response to stress |
| AQP2 | Water channel; trafficked by Rab7/Vps35 | Dysregulation affects renal function and lysosomal trafficking |
| VEGFR2 | Vascular endothelial growth factor receptor 2 | Recycling by KIF13B affects vascular permeability |
| Abemaciclib targets | CDK4/6 inhibitors; resistance linked to lysosomal deregulation | Resistant breast cancer cells show increased lysosomal permeability |
| Mitochondrial regulators | Proteins affecting mitochondrial dysfunction | Linked to NAFLD amelioration via nanotherapeutics |
How Is positive regulation of lysosomal membrane permeability Regulated?
The positive regulation of lysosomal membrane permeability is controlled by multiple mechanisms. Transcriptional regulation by p53 can induce DRAM, which directly permeabilizes lysosomes. Trafficking pathways involving Rab7 and Vps35 influence lysosomal membrane composition and dynamics. KIF13B-mediated recycling of VEGFR2 affects vascular permeability, suggesting that endosomal trafficking can indirectly modulate lysosomal membrane stability. Additionally, lysosomal acidification, as studied in rat liver lysosomes, is a key regulator; changes in pH can alter membrane integrity. Metabolic signals, such as those in non-alcoholic fatty liver disease, can also impact lysosomal function and permeability.
positive regulation of lysosomal membrane permeability and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DRAM | HIV infection, CD4+ T cell death | Knockout of DRAM in CD4+ T cells followed by HIV infection |
| LAMP5 | Intracerebral hemorrhage brain injury | LAMP5 knockout mice subjected to ICH |
| Rab7 | Renal water transport disorders | Rab7 knockout in collecting duct cells |
| KIF13B | Vascular permeability disorders | KIF13B knockout endothelial cells |
| Abemaciclib resistance | Breast cancer metastasis | Resistant breast cancer cell lines with lysosomal protein knockdown |
Cancer and drug resistance
In breast cancer cells resistant to abemaciclib, lysosomal protein deregulation is associated with increased metastatic potential and altered lysosomal membrane permeability. This suggests that positive regulation of lysosomal membrane permeability may contribute to drug resistance and cancer progression. Targeting lysosomal permeability could be a strategy to overcome resistance.
HIV infection and T cell death
DRAM triggers lysosomal membrane permeabilization and cell death in CD4+ T cells infected with HIV. This process contributes to CD4+ T cell depletion, a hallmark of AIDS progression. Understanding how DRAM regulates lysosomal permeability may inform therapies to preserve immune function.
Neurodegeneration and brain injury
LAMP5, a lysosomal-associated transmembrane protein, plays a role in intracerebral hemorrhage-induced brain injury. Dysregulation of lysosomal membrane permeability may exacerbate neuronal damage. Modulating this process could be neuroprotective.
Metabolic liver disease
Microenvironment-induced nanotherapeutics restore mitochondrial dysfunction and ameliorate non-alcoholic fatty liver disease, partly by affecting lysosomal function. Lysosomal membrane permeability may be involved in the pathogenesis of metabolic liver disease, offering a therapeutic target.
From positive regulation of lysosomal membrane permeability-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does DRAM cause lysosomal membrane permeabilization? | DRAM knockout cell line (e.g., CD4+ T cells) |
| What is the role of LAMP5 in brain injury? | LAMP5 knockout mouse model of intracerebral hemorrhage |
| How does Rab7 regulate lysosomal trafficking? | Rab7 knockout or knockdown in renal collecting duct cells |
| Does KIF13B affect vascular permeability? | KIF13B knockout endothelial cells |
| Can overexpression of TFEB increase lysosomal permeability? | TFEB overexpression cell lines |
| What mutations in LAMP2 affect membrane stability? | LAMP2 point mutation knock-in models |
How to Study the positive regulation of lysosomal membrane permeability Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Acridine orange staining | Lysosomal membrane integrity | Quantify permeabilization after drug treatment |
| Cathepsin activity assay | Release of lysosomal proteases | Measure cytosolic cathepsin activity |
| Galectin-3 puncta | Lysosomal membrane damage | Visualize permeabilization by microscopy |
| Live-cell imaging | Real-time lysosomal dynamics | Track LAMP1-GFP distribution |
| Proteomics | Protein composition of lysosomes | Identify changes in membrane proteins |
| RNA-seq | Transcriptional changes | Assess DRAM, LAMP5 expression |
| CRISPR screen | Genes regulating permeability | Identify modifiers of lysosomal leakage |
| Lysosomal pH measurement | Acidification status | Correlate pH with permeability |
Lysosomal membrane permeability assays
These assays measure the leakage of lysosomal contents, such as cathepsins, into the cytosol. Common methods include acridine orange staining, cathepsin activity assays, and galectin-3 puncta formation. They are used to quantify the extent of lysosomal membrane permeabilization after genetic or pharmacological manipulation.
Live-cell imaging
Live-cell imaging with fluorescently tagged lysosomal markers (e.g., LAMP1-GFP) allows real-time visualization of lysosomal membrane integrity and permeability. This method can track the dynamics of pore formation and content release in response to stimuli.
Proteomics and transcriptomics
Mass spectrometry-based proteomics can identify proteins released from lysosomes or changes in lysosomal membrane composition. RNA-seq can reveal transcriptional changes in genes regulating lysosomal permeability, such as DRAM and LAMP5 [1, 4].
CRISPR screening
Genome-wide CRISPR knockout or activation screens can identify genes that positively or negatively regulate lysosomal membrane permeability. These screens use reporters of lysosomal leakage or cell death to select for modifiers [1, 7].
How CRISPR Can Be Used to Study GO:0097214 positive regulation of lysosomal membrane permeability
Knockout
CRISPR knockout of genes such as DRAM, LAMP5, Rab7, or KIF13B can determine their necessity for positive regulation of lysosomal membrane permeability. For example, DRAM knockout reduces lysosomal membrane permeabilization and cell death in HIV-infected T cells. LAMP5 knockout exacerbates brain injury in intracerebral hemorrhage models.
Point Mutation
Point mutations can be introduced to mimic disease-associated variants or to dissect functional domains. For instance, mutating specific residues in LAMP2 or DRAM may alter their ability to regulate lysosomal membrane permeability. These models help link specific amino acids to membrane stability [4, 8].
Knock-in
Knock-in of tagged versions of lysosomal proteins (e.g., LAMP1-GFP) allows visualization and quantification of lysosomal membrane dynamics. Knock-in of disease-relevant mutations can model human conditions and test therapeutic interventions [3, 7].
Overexpression
Overexpression of positive regulators such as DRAM or TFEB can increase lysosomal membrane permeability and induce cell death or autophagy. These models are useful for screening protective compounds or identifying downstream effectors [3, 8].
How EDITGENE Supports positive regulation of lysosomal membrane permeability Research
Researchers studying positive regulation of lysosomal membrane permeability-related genes often need to determine whether a candidate gene is causally involved in membrane permeabilization, content release, or downstream cellular responses. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of lysosomal membrane permeability research.
Frequently Asked Questions About positive regulation of lysosomal membrane permeability
What is GO:0097214?
GO:0097214 is the Gene Ontology term for positive regulation of lysosomal membrane permeability, defined as any process that increases the frequency, rate or extent of molecule passage or uptake by the lysosomal membrane [1, 6].
What genes are involved in positive regulation of lysosomal membrane permeability?
Key genes include DRAM, LAMP5, Rab7, Vps35, KIF13B, and cathepsins, among others [2, 4, 7, 8].
How is lysosomal membrane permeability measured?
It is measured using assays such as acridine orange staining, cathepsin activity assays, galectin-3 puncta, and live-cell imaging with LAMP1-GFP [3, 8].
What diseases are linked to lysosomal membrane permeability?
It is linked to HIV infection, cancer drug resistance, intracerebral hemorrhage, neurodegeneration, and metabolic liver disease [1, 4, 5, 8].
What is the role of DRAM in lysosomal membrane permeability?
DRAM triggers lysosomal membrane permeabilization and cell death in CD4+ T cells infected with HIV.
How does LAMP5 affect lysosomal membrane permeability?
LAMP5 is a lysosomal-associated transmembrane protein that may stabilize the membrane; its knockout worsens brain injury after intracerebral hemorrhage.
Can CRISPR be used to study lysosomal membrane permeability?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect gene function in this process [1, 4, 7].
What is the connection between Rab7 and lysosomal membrane permeability?
Rab7 mediates lysosomal trafficking and, with Vps35, regulates AQP2 sorting; its dysfunction can alter lysosomal membrane dynamics.
How does KIF13B influence vascular permeability?
KIF13B mediates VEGFR2 recycling, which modulates vascular permeability, indirectly affecting lysosomal membrane dynamics.
What methods are used to study positive regulation of lysosomal membrane permeability?
Common methods include lysosomal permeability assays, live-cell imaging, proteomics, RNA-seq, and CRISPR screens [1, 3, 8].
Conclusion
GO:0097214, positive regulation of lysosomal membrane permeability, is a critical biological process that governs the release of lysosomal contents and influences cell fate. Its dysregulation is implicated in cancer, HIV pathogenesis, brain injury, and metabolic disease. Understanding the genes and mechanisms involved provides opportunities for therapeutic intervention. EDITGENE offers comprehensive CRISPR services to study this process and accelerate discovery.
References
- 1. Scheidemann ER et al.. 2024. Resistance to abemaciclib is associated with increased metastatic potential and lysosomal protein deregulation in breast cancer cells.. Mol Carcinog 63(2):209-223 PMID: 37818798
- 2. Cho HD et al.. 2023. KIF13B mediates VEGFR2 recycling to modulate vascular permeability.. Cell Mol Life Sci 80(4):91 PMID: 36928770
- 3. Ivanov A et al.. 2013. Lysosome-mediated processing of chromatin in senescence.. J Cell Biol 202(1):129-43 PMID: 23816621
- 4. Hua W et al.. 2023. Intracerebral Hemorrhage-Induced Brain Injury: the Role of Lysosomal-Associated Transmembrane Protein 5.. Mol Neurobiol 60(12):7060-7079 PMID: 37525083
- 5. Zhang J et al.. 2025. Microenvironment-induced programmable nanotherapeutics restore mitochondrial dysfunction for the amelioration of non-alcoholic fatty liver disease.. Acta Biomater 194:323-335 PMID: 39805524
- 6. Van Dyke RW. 1993. Acidification of rat liver lysosomes: quantitation and comparison with endosomes.. Am J Physiol 265(4 Pt 1):C901-17 PMID: 8238315
- 7. Wang WL et al.. 2020. Rab7 involves Vps35 to mediate AQP2 sorting and apical trafficking in collecting duct cells.. Am J Physiol Renal Physiol 318(4):F956-F970 PMID: 32088968
- 8. Laforge M et al.. 2013. DRAM triggers lysosomal membrane permeabilization and cell death in CD4(+) T cells infected with HIV.. PLoS Pathog 9(5):e1003328 PMID: 23658518
